Takeda director Fujimori reports equity holdings

Takeda Pharmaceutical director Yoshiaki Fujimori filed an initial ownership report listing his equity interests in the company.

Rhea-AI Filing Summary

Takeda Pharmaceutical director Yoshiaki Fujimori filed an initial ownership report listing his equity interests in the company. He directly holds 27,865 Ordinary Shares. The filing also notes 8,400 restricted stock units (RSUs), each representing a right to receive one Ordinary Share as they vest.

The RSUs vest on June 1, 2026 (2,100 shares), June 1, 2027 (2,200 shares), June 1, 2028 (2,100 shares) and upon retirement from board service (2,000 shares). Separate Tax Obligation Awards are described as economically equivalent to Ordinary Shares but payable in cash primarily to cover tax obligations at future vesting.

Insider Trade Summary

5 transactions reported

Mixed 5 txns

Insider FUJIMORI YOSHIAKI

Role Director

Type	Security	Shares	Price	Value
holding	Tax Obligation Award	--	--	--
holding	Tax Obligation Award	--	--	--
holding	Tax Obligation Award	--	--	--
holding	Tax Obligation Award	--	--	--
holding	Ordinary Shares	--	--	--

Holdings After Transaction: Tax Obligation Award — 9,342 contracts (Direct); Ordinary Shares — 27,865 shares (Direct)

Footnotes (3)

1. F1. Includes an award of 8,400 restricted stock units (RSUs). Each RSU represents a contingent right to receive one Ordinary Share. The RSUs vest on the following schedule: June 1, 2026 (2,100 shares), June 1, 2027 (2,200 shares), June 1, 2028 (2,100 shares) and upon retirement from board service (2,000 shares).
2. F2. Each Tax Obligation Award is the economic equivalent of one Ordinary Share that, upon vest, will be converted to a cash payment primarily to cover tax obligations at the then-current market price of the Ordinary Shares.
3. F3. Vests upon conclusion of the director's service on the board.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does Takeda (TAK) director Yoshiaki Fujimori report owning in this Form 3?

He reports direct ownership of 27,865 Ordinary Shares of Takeda Pharmaceutical. The filing also references 8,400 restricted stock units (RSUs) and Tax Obligation Awards that are economically tied to Ordinary Shares, providing additional equity-linked compensation over time.

How many restricted stock units does Takeda (TAK) director Fujimori hold and how do they vest?

He holds an award of 8,400 RSUs, each representing one Ordinary Share. Vesting occurs on June 1, 2026 (2,100), June 1, 2027 (2,200), June 1, 2028 (2,100) and upon retirement from board service (2,000), aligning compensation with board tenure.

What are the Tax Obligation Awards disclosed for Takeda (TAK) director Fujimori?

The Tax Obligation Awards are described as the economic equivalent of one Ordinary Share each. Upon vesting, they convert into a cash payment at the then-current Ordinary Share market price, primarily to cover tax obligations related to his equity compensation.

Does this Takeda (TAK) Form 3 show any share purchases or sales by director Fujimori?

No explicit purchases or sales are identified in the data provided. The entries are classified as holding records, reflecting existing Ordinary Share ownership, RSUs and Tax Obligation Awards, rather than new open-market transactions or disposals of Takeda shares.

How do the RSUs reported by Takeda (TAK) director Fujimori relate to Ordinary Shares?

Each RSU represents a contingent right to receive one Ordinary Share of Takeda when it vests. This structure links part of the director’s compensation directly to the company’s equity, aligning long-term incentives with shareholder interests over his board service period.

When do certain Takeda (TAK) equity awards for director Fujimori fully vest?

RSUs are scheduled to vest in tranches on June 1, 2026, June 1, 2027, June 1, 2028, and upon his retirement from board service. Additional Tax Obligation Awards vest on specified future dates, paying cash tied to the Ordinary Share market price.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/18/2026 - 06:17 AM Learn about SEC filing dates

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

FUJIMORI YOSHIAKI

(Last) (First) (Middle)

300 BOSTON SCIENTIFIC WAY

(Street)

MARLBOROUGH MASSACHUSETTS 01752

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
TAKEDA PHARMACEUTICAL CO LTD [ TAK ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Ordinary Shares	27,865(1)	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Tax Obligation Award	06/01/2026	06/01/2026	Ordinary Shares	2,152	(2)	D
Tax Obligation Award	06/01/2027	06/01/2027	Ordinary Shares	2,392	(2)	D
Tax Obligation Award	06/01/2028	06/01/2028	Ordinary Shares	2,280	(2)	D
Tax Obligation Award	(3)	(3)	Ordinary Shares	2,518	(2)	D

Explanation of Responses:

1. Includes an award of 8,400 restricted stock units (RSUs). Each RSU represents a contingent right to receive one Ordinary Share. The RSUs vest on the following schedule: June 1, 2026 (2,100 shares), June 1, 2027 (2,200 shares), June 1, 2028 (2,100 shares) and upon retirement from board service (2,000 shares).

2. Each Tax Obligation Award is the economic equivalent of one Ordinary Share that, upon vest, will be converted to a cash payment primarily to cover tax obligations at the then-current market price of the Ordinary Shares.

3. Vests upon conclusion of the director's service on the board.

Remarks:

Exhibit 24 Power of Attorney

	/s/ Max Heuer, by power of attorney, for Yoshiaki Fujimori	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)